Claritas HealthTech conducts imaging software study with UK-based radiologists

KUALA LUMPUR, Nov 25 (Bernama) -- Singaporean healthcare technology company Claritas HealthTech Pte Ltd will be researching the effectiveness of iRAD, its image enhancement Software as a Medical Device (SaMD), across modalities and conditions with leading UK-based consultant radiologists.

Claritas said the UK’s National Health Service (NHS) had granted the company access to its National Covid-19 Chest Imaging Database (NCCID) lab to facilitate the study.

The study will evaluate data across modalities (X-Rays, CT and MRI) using multiple clinical, operational and quality parameters for the benefit of patient outcomes.

“Recognising the need to evaluate the performance of new technologies with data representative of the population and by clinicians delivering that care, Claritas has designed a study to evaluate the benefits of iRAD with data that is representative of that population,” said Claritas chief clinical strategy officer Dr Arup Paul.

Paul said parameters under assessment would include the optimisation of technical image quality, improvements in clinician interpretation, lesion identification and the potential of these enhanced data sets.

“The evaluation of iRAD using the NCCID could deliver benefits for patients and clinicians in multiple parts of the health ecosystem from screening programmes, accident and emergency to complex intervention planning,” he added.

-- BERNAMA